Title : Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2.

Pub. Date : 2012 Sep

PMID : 22609309






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 After an in vitro study in a hepatocellular polarized line, we tested 4-PB treatment in a child with a homozygous p.T1210P BSEP mutation. 4-phenylbutyric acid ATP binding cassette subfamily B member 11 Homo sapiens
2 4-PB as well as incubation at 27 C partially corrected Bsep(T1210P)-GFP targeting to the canalicular membrane, while combined treatments resulted in normal canalicular localization. 4-phenylbutyric acid ATP binding cassette subfamily B member 11 Homo sapiens
3 CONCLUSIONS: The results illustrate for the first time the therapeutic potential of a clinically approved chaperone drug in a selected patient with PFIC2 and support that bile secretion improvement might be due to the ability of 4-PB to retarget mutated BSEP. 4-phenylbutyric acid ATP binding cassette subfamily B member 11 Homo sapiens
4 CONCLUSIONS: The results illustrate for the first time the therapeutic potential of a clinically approved chaperone drug in a selected patient with PFIC2 and support that bile secretion improvement might be due to the ability of 4-PB to retarget mutated BSEP. 4-phenylbutyric acid ATP binding cassette subfamily B member 11 Homo sapiens